At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Trading 04-15 10:38:59 EDT
1.90
-0.05
-2.56%
High1.99Low1.86Vol533.28K
Open1.97D1 Closing1.95Amplitude6.67%
Mkt Cap137.37MTradable Cap128.14MTotal Shares72.30M
T/O1.01MT/O Rate0.79%Tradable Shares67.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story
TIPRANKS  ·  04-09
Biomea Fusion Advances Mid‑Stage Diabetes Trial, Adding a New Angle to the BMEA Investment Story
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  04-08
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Biomea Fusion Inc: Topline 26-Week Primary Endpoint Data From Both Phase Ii Studies Anticipated 4Q 2026
THOMSON REUTERS  ·  03-31
Biomea Fusion Inc: Topline 26-Week Primary Endpoint Data From Both Phase Ii Studies Anticipated 4Q 2026
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
GlobeNewswire  ·  03-31
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion Is Maintained at Buy by Citigroup
Dow Jones  ·  03-27
Biomea Fusion Is Maintained at Buy by Citigroup
Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’
TIPRANKS  ·  03-27
Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’
Biomea Fusion Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-26
Biomea Fusion Inc reports results for the quarter ended December 31 - Earnings Summary
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  03-25
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Biomea Fusion (BMEA)
TIPRANKS  ·  03-25
Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Biomea Fusion (BMEA)
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)
TIPRANKS  ·  03-25
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Biomea Fusion (BMEA)
Biomea Fusion Q4 EPS $0.27 Beats $(0.23) Estimate
Benzinga  ·  03-25
Biomea Fusion Q4 EPS $0.27 Beats $(0.23) Estimate
Press Release: Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Dow Jones  ·  03-25
Press Release: Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
TIPRANKS  ·  03-15
Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes
Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients
Reuters  ·  03-14
Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients
Biomea Fusion management to meet virtually with Craig-Hallum
TIPRANKS  ·  03-04
Biomea Fusion management to meet virtually with Craig-Hallum
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
TIPRANKS  ·  02-25
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference
Reuters  ·  02-19
Biomea Fusion to Present at Oppenheimer Healthcare Life Sciences Conference
Biomea Fusion to Participate at Upcoming Investor Conferences
GlobeNewswire  ·  02-19
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
TIPRANKS  ·  01-15
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
Biomea Fusion initiated with a Buy at Rodman & Renshaw
TIPRANKS  ·  01-14
Biomea Fusion initiated with a Buy at Rodman & Renshaw

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--